Mosanna Therapeutics AG closes Seed Financing Round

Mosanna Therapeutics AG, a Basel-based biotechnology company developing the advanced small molecule MOS118 (formerly know as AVE0118) for the treatment of metabolic obstructive sleep apnea, closes a Seed Financing Round led by Forty51 Ventures. The proceeds will be used for formulation and manufacturing optimization of MOS118 and for regulatory activities in preparation of the first Phase 1b clinical trial.
VISCHER advises Mosanna Therapeutics AG since its incorporation on all Swiss legal matters.

The VISCHER team includes Matthias Staehelin (Partner) and Timothy Woodtli (Associate), both Corporate/M&A.

Matthias Staehelin

Attorney at Law and Civil Law Notary (BS/BL)

• Partner

• +41 58 211 33 53
• [email protected]

Timothy Woodtli

Attorney at Law

• Senior Associate

• +41 58 211 32 20
• [email protected]